Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Growth Hormone & IGF Research
The nutrients in lipotropic injections support liver function, aiding in detoxification and promoting better liver health
Key Features D-retro-inverso peptide model for in vitro research Suitable for studies involving FOXO-associated proteinprotein interactions Used in controlled investigations of senescence-related cellular pathways Supplied as a lyophilised powder for convenient handling and storage 10 mg per vial Released only after internal quality control review Specifications for FOXO4-DRI Product name: FOXO4-DRI Also known as: FOXO4 DRI, FOXO4 peptide (D-retro-inverso), FOX04, FOX04-DRI Class: Peptide analogue (research use) Form: Lyophilised powder Unit size: 10 mg Appearance: White to off-white solid Lot note: Counter-ion content and hydration state may vary between batches
As a result, the oxidative stress is reduced, and the skin appears brighter and clearer
Each of these side effects is temporary and improve gradually over time
The FDA announced the action on April 15, 2026 (Federal Register notice April 16), and the peptides come off the Category 2 list effective April 23, 2026
